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Treatment of Atrial Fibrillation
by the Ablation of Localized Sources
CONFIRM (Conventional Ablation for Atrial Fibrillation
With or Without Focal Impulse and Rotor Modulation) Trial
Sanjiv M. Narayan, MD, PHD,*† David E. Krummen, MD,*† Kalyanam Shivkumar, MD, PHD,‡
Paul Clopton, MS,† Wouter-Jan Rappel, PHD,§ John M. Miller, MD
San Diego and Los Angeles, California; and Indianapolis, Indiana
Objectives We hypothesized that human atrial fibrillation (AF) may be sustained by localized sources (electrical rotors and
focal impulses), whose elimination (focal impulse and rotor modulation [FIRM]) may improve outcome from AF
ablation.
Background Catheter ablation for AF is a promising therapy, whose success is limited in part by uncertainty in the mecha-
nisms that sustain AF. We developed a computational approach to map whether AF is sustained by several me-
andering waves (the prevailing hypothesis) or localized sources, then prospectively tested whether targeting
patient-specific mechanisms revealed by mapping would improve AF ablation outcome.
Methods We recruited 92 subjects during 107 consecutive ablation procedures for paroxysmal or persistent (72%) AF.
Cases were prospectively treated, in a 2-arm 1:2 design, by ablation at sources (FIRM-guided) followed by con-
ventional ablation (n  36), or conventional ablation alone (n  71; FIRM-blinded).
Results Localized rotors or focal impulses were detected in 98 (97%) of 101 cases with sustained AF, each exhibiting
2.1  1.0 sources. The acute endpoint (AF termination or consistent slowing) was achieved in 86% of FIRM-
guided cases versus 20% of FIRM-blinded cases (p  0.001). FIRM ablation alone at the primary source termi-
nated AF in a median 2.5 min (interquartile range: 1.0 to 3.1 min). Total ablation time did not differ between
groups (57.8  22.8 min vs. 52.1  17.8 min, p  0.16). During a median 273 days (interquartile range: 132
to 681 days) after a single procedure, FIRM-guided cases had higher freedom from AF (82.4% vs. 44.9%;
p  0.001) after a single procedure than FIRM-blinded cases with rigorous, often implanted, electrocardiography
monitoring. Adverse events did not differ between groups.
Conclusions Localized electrical rotors and focal impulse sources are prevalent sustaining mechanisms for human AF. FIRM
ablation at patient-specific sources acutely terminated or slowed AF, and improved outcome. These results offer
a novel mechanistic framework and treatment paradigm for AF. (Conventional Ablation for Atrial Fibrillation
With or Without Focal Impulse and Rotor Modulation [CONFIRM]; NCT01008722) (J Am Coll Cardiol 2012;60:
628–36) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.022Atrial fibrillation (AF) is the most common heart rhythm
disturbance in the world and a leading cause of hospitaliza-
tion and death (1). Unfortunately, its therapy remains subop-
timal. Catheter ablation is a nonpharmacological therapy that
aims to restore sinus rhythm by eliminating tissue causing AF
(2,3), and is more effective than medications (4–6). Neverthe-
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“silent” AF after ablation (7). Accordingly, the 1-year success
for AF ablation off medications is 40% to 60% for 1 procedure
(3,8,9) with a “70% ceiling” for 3 or more procedures
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August 14, 2012:628–36 Ablation at AF Sources(3,5,6,10). Thus, many patients require multiple, lengthy, and
costly procedures that confer at least modest risk (3).
Contemporary AF ablation is likely limited by 2 main
factors. First, current tools may not create durable lesions,
evidenced by pulmonary vein reconnection (11,12) and gaps
in linear lesions (10,13) in patients with recurrent AF after
ablation. However, an important second major limitation of
AF ablation is that the mechanisms that sustain AF are not
identified (3,14,15), in contrast to all other arrhythmias in
which the perpetuating mechanism is the primary target for
ablation.
Seminal observations by Haïssaguerre et al. (2) revealed
that ectopic beats from the pulmonary veins may trigger AF,
establishing the field of AF ablation with pulmonary vein
isolation as its cornerstone (3). However, the mechanisms
that sustain paroxysmal or persistent AF, once triggered, are
not defined (14,16). There are 2 prevailing hypotheses. The
multiwavelet hypothesis proposes that continuously mean-
dering electrical waves cause AF (15). However, this hy-
pothesis does not readily explain spatial nonuniformities in
AF (17,18), the fact that AF may terminate early in a
procedure often before meandering wavelets are substan-
tially constrained (3,10), yet the fact that ablation based on
this hypothesis often has little acute periprocedural impact
(3,19). Alternatively, the localized source hypothesis is
based on experimental models in which organized reentrant
circuits (rotors) (16,20) or focal impulses (18) disorganize
into AF. However, there has been little (21,22) or no (15)
evidence to support localized sources in human AF.
We hypothesized that human AF, even with a wide range
of presentations, is sustained by localized sources whose
targeted elimination may improve outcome after AF abla-
tion. We tested this hypothesis by developing a novel
computational mapping approach to detect localized
sources, then tested whether ablation of patient-specific AF
sources, namely, focal impulse and rotor modulation
(FIRM), acutely modulates AF (by terminating or consis-
tently slowing AF), and improves the long-term success of
conventional ablation in the CONFIRM (Conventional
Ablation With or Without FIRM) trial.
Methods
Study design and enrollment. We enrolled 92 subjects
with symptomatic AF undergoing 107 consecutive ablation
procedures for standard indications (3) under specific insti-
tutional review board-approved informed consent. Subjects
were 21 years of age, with AF despite 1 or more class I or
II antiarrhythmic drugs, and diverse phenotypes including
aroxysmal AF (self-limiting episodes), persistent AF
requiring drugs or electrical shock to terminate), long-
tanding persistent AF (continuous AF for 1 year) (3),
and AF despite prior conventional ablation. The only
exclusion was an inability or refusal to provide written
informed consent for this study. Table 1 summarizes the
patient characteristics.All patients were recruited
prospectively under specific insti-
tutional review board approval.
We performed detailed AF re-
cordings and used computational
mapping to reveal localized
sources (23), as detailed in the
Supplementary Methods (Online
Appendix). Processing initially
took days and could not be used to guide ablation. However,
once computational efficiency made it possible to map
sources intraprocedurally, we registered the CONFIRM
trial. Consecutive cases were thus prospectively enrolled in a
2-arm 1:2 case cohort design into the FIRM-guided group
whenever intraprocedural mapping was available, or the
FIRM-blinded group, blinded to any clinical factors. The
FIRM-guided group received targeted ablation of sources
followed by conventional ablation (by S.M.N. or D.E.K. at
2 centers), whereas the FIRM-blinded group received
conventional ablation alone (by S.M.N., D.E.K., or K.S.) at
3 centers.
Electrophysiology study. Electrophysiology study was
performed after discontinuing antiarrhythmic medications
for 5 half-lives, or 60 days for amiodarone (median 230
days) (Table 1). Catheters were advanced from the femoral
veins to the right atrium, coronary sinus and transseptally to
the left atrium. A 64-pole basket catheter (Constellation,
Boston Scientific, Natick, Massachusetts) was advanced
through an 8.5F SL1 sheath (Daig Medical, Minnetonka,
Minnesota) to map the left atrium with a wide field of view
in all patients. In 73 patients (including all FIRM-guided
cases), basket mapping was also performed in the right
atrium. Basket insertion (1 min) was then followed by
careful positioning (5 min). Digital electroanatomic atrial
shells were created for clinical guidance of conventional
ablation (not FIRM) using NavX (St. Jude Medical, Min-
neapolis, Minnesota) or Carto (Biosense-Webster, Dia-
mond Bar, California) systems. Intravenous heparin was
infused to achieve an activated clotting time 350 s in all
cases. Figure 1 shows AF (Fig. 1A) mapped with 1 basket
in the left atrium across a transseptal puncture and another
in the right atrium (Fig. 1B). Unipolar and bipolar electro-
grams were filtered at 0.05 Hz to 500 Hz and recorded at 1
kHz sampling frequency for export from our physiological
recorder (Bard, Lowell, Massachusetts).
In any patient presenting in sinus rhythm (n  28), AF
as induced by pacing at cycle length 500 ms (120 beats/min),
educing in 50 ms steps to 300 ms (200 beats/min), then in 10
s steps to AF. In 2 cases, isoproterenol was required to
nitiate AF, and was maintained throughout the proce-
ure. Induced AF was mapped after 15 min, and
typically after 1 h to 2 h since induction was performed
early in the case, based on preliminary data that spatial
maps of induced and spontaneous AF converge within
Abbreviations
and Acronyms
AF  atrial fibrillation
ECG  electrocardiography
FIRM  focal impulse and
rotor modulation
IQR  interquartile rangethis time.
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Ablation at AF Sources August 14, 2012:628–36Sustained AF was seen, and FIRM maps created, in 101 cases
(including all FIRM-guided cases). The remaining 6 FIRM-
blinded cases underwent conventional ablation in sinus rhythm.
Computationalmappingofpatient-specificAFmechanisms.
The physiological rationale, algorithms, and approach we
have developed for AF mapping have recently been de-
scribed (23) and are detailed in the Supplemental Methods
(see Online Appendix). Briefly, AF electrograms are ana-
lyzed in the context of rate-dependent repolarization
(24,25), that indicate the shortest physiological time be-
tween successive activations during AF, and rate-dependent
conduction slowing (26), used to identify mapped propaga-
tion paths that were physiologically possible. The resulting
computational maps depict the propagation of electrical
activity, color coded from early (in red) to late (in blue), in
Characteristics of Clinical CasesTable 1 Characteristics of Clinical Cases
Characteristics
Conventional
Ablation
(n  71)
FIRM-Guided
Ablation
(n  36) p Value
AF presentation 0.12
Paroxysmal 24 (34%) 7 (19%)
Persistent 47 (66%) 29 (81%)
Age, yrs 61 8 63 9 0.34
Male/female 68/3 34/2 1.00
Nonwhite race 9 (13%) 6 (17%) 0.57
History of AF, months 45 (18–79) 52 (38–110) 0.04
Left atrial diameter, mm 43 6 48 7 0.001
LVEF, % 55 12 53 15 0.59
CHADS2 score
0 or 1 38 (54%) 13 (36%) 0.09
2 or more 33 (46%) 23 (64%)
NYHA functional class 0.47
0 to I 61 (86%) 29 (81%)
II to III 10 (14%) 7 (19%)
Comorbid conditions
Hypertension 50 (70%) 31 (86%) 0.07
Diabetes mellitus 22 (31%) 12 (33%) 0.81
Prior stroke/TIA 12 (17%) 6 (17%) 0.95
Coronary disease 20 (28%) 18 (50%) 0.03
Hypercholesterolemia 48 (68%) 30 (86%) 0.05
Prior conventional ablation 18 (25%) 15 (42%) 0.08
Previously failed 1 antiarrhythmic drug 16 (23%) 16 (44%) 0.05
Class I 16 (23%) 9 (25%) 0.78
Sotalol 30 (42%) 17 (47%) 0.63
Dofetilide 9 (13%) 8 (22%) 0.20
Amiodarone 27 (38%) 22 (61%) 0.02
Days since amiodarone discontinued 150 (60–365) 365 (69–730) 0.08
Concomitant drug therapy
ACEI/ARB 45 (63%) 21 (58%) 0.61
Beta-adrenoceptor antagonists 48 (68%) 24 (67%) 0.92
Calcium-channel blockers 21 (30%) 11 (31%) 0.92
Statins 42 (59%) 19 (53%) 0.53
Values are n (%), mean  SD, or median (interquartile range).
ACEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; ARB  angiotensin-
receptor blocker; CHADS2  defined in Calkins et al. (3); FIRM  focal impulse and rotor
modulation; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association;
TIA  transient ischemic attack.each atrium (Fig. 1C). 9Computational AF maps were generated intraprocedur-
ally in the FIRM-guided group, and post-procedure in the
FIRM-blinded group using a novel system (RhythmView,
Topera Medical, Lexington, Massachusetts). The FIRM
maps of AF revealed electrical rotors (Figs. 1C and 2A)
defined as sequential clockwise or counterclockwise activa-
tion contours (isochrones) around a center of rotation
emanating outward to control local AF activation, or focal
impulses (Fig. 2C) defined by centrifugal activation con-
tours (isochrones) from an origin. Rotors and focal impulses
showed limited spatial precession (see following text) and
were considered AF sources only if consistent in multiple
recordings over 10 min (equating to thousands of cycles)
to eliminate transient AF patterns of unclear functional
significance.
Ablation procedure. In FIRM-guided subjects, ablation
commenced with FIRM to eliminate sources. Radiofre-
quency energy was delivered using a 3.5-mm tip irrigated
catheter (Thermocool, Biosense-Webster) at 25 W to 35 W
or, in heart failure subjects, an 8-mm tip nonirrigated
catheter (Blazer, Boston Scientific, Natick, Massachusetts)
at 40 W to 50 W, target 52°C. The catheter was maneu-
vered to the basket electrode overlying each source, using
fluoroscopy (or digital atrial mapping), and radiofrequency
energy was applied for 15 s to 30 s. The catheter was moved
within the area indicated by FIRM maps to represent the
center of rotation or focal impulse origin until AF termi-
nated or ablation time at that source reached 10 min,
whichever came first (typically 5 min per source). If AF
terminated, attempts were made to reinitiate AF using the
protocol described for AF initiation. If AF was successfully
reinitiated, FIRM ablation was repeated for 3 sources
(30 min permitted by protocol). Conventional ablation
was then performed.
Conventional ablation (3), performed after FIRM abla-
tion in the FIRM-guided group, and as sole therapy in the
FIRM-blinded group, comprised wide area circumferential
ablation to isolate the left and right pulmonary veins in
pairs, with verification of pulmonary vein isolation using a
circular mapping catheter (Lasso, Biosense-Webster). Ab-
lation power, temperatures, and duration were as noted for
the FIRM-guided group. In cases of persistent AF, we also
used a left atrial roof line; atrial tachycardia or flutter (n 
cases) were ablated appropriately. No other ablation was
erformed. If AF persisted after completion of the ablation
rotocol in each group, cardioversion was performed. An
sophageal temperature probe was maintained in proximity
o the catheter during ablation, and energy was discontinued
f a 1°C rise in temperature was noted.
ost-procedure clinical management. Follow-up for re-
urrent arrhythmias met or exceeded guidelines (3). Within
3-month blanking period post-ablation, antiarrhythmic
edications were continued, and arrhythmias were man-
ged with cardioversion if indicated. However, repeat abla-
ion was not permitted. Subjects were then evaluated at 3, 6,
, 12, 18, and 24 months. We detected recurrent arrhyth-
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(ECG) monitors whenever possible, using Reveal XT
(Medtronic, Minneapolis, Minnesota) after its U.S. ap-
Figure 1 Computational Mapping of “Electrical Rotor” During A
(A) Electrocardiogram (ECG) and intracardiac signals in an 85-year-old man during
atrium, an implanted continuous electrocardiography (ECG) monitor, diagnostic cat
the inferior left atrium. (C) Left atrial rotor during AF, showing clockwise revolution
cycles (AF1 to AF3; Online Video 1). The right atrium depicts the superior and infe
right. The left atrium depicts superior and inferior mitral annuli above and below, a
atrium depicts the superior and inferior vena cavae above and below, and lateral a
mitral annuli above and below, and pulmonary vein pairs. Electrodes are labeled A
nals show sequential activation over the rotor path for cycles AF1 to AF3 (arrowed
sinus rhythm in 1 min (Online Videos 2 and 3).
Figure 2 Acute Termination of AF to Sinus Rhythm By FIRM Ab
(A) Left atrial rotor with counterclockwise activation (red to blue) and disorganized
rotor modulation (FIRM) ablation at left atrial rotor terminated AF to sinus rhythm i
implanted cardiac monitor at 1 year. Scale bars 1 cm, 1 s. Atrial orientations asproval in 2009 (Fig. 1B), or clinically indicated pacemaker/
defibrillators with AF detection algorithms. Continuous
monitors were interrogated at scheduled visits and at in-
Fibrillation
smal atrial fibrillation (AF). (B) Fluoroscopy shows a 64-pole catheter in each
in the coronary sinus and left atrium, and an esophageal temperature probe at
d red to blue based on activation time scale) around a precessing center for 3
na cavae above and below, and lateral and medial tricuspid annuli at left and
lmonary vein pairs. Electrodes are labeled A to H (Online Video 1). The right
dial tricuspid annuli at left and right. The left atrium depicts superior and inferior
to 8, respectively. (D) Computationally processed and filtered intracardiac sig-
focal impulse and rotor modulation (FIRM) ablation at this rotor terminated AF to
n
atrium during atrial fibrillation (AF) in a 60-year-old man. (B) Focal impulse and
min, with ablation artifact recorded at rotor center. The patient is AF-free on
ure 1. CS  coronary sinus electrogram.trial
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Ablation at AF Sources August 14, 2012:628–36terim visits for symptoms by nurses, then over-read by a
physician, both blinded to the ablation approach. Implanted
ECG monitors provide more rigorous monitoring (7,27)
than in most prior AF treatment trials. Remaining subjects
received 7-day patient-activated event recorders or 24-h
ambulatory ECG at each visit.
Study endpoints. The pre-specified acute efficacy endpoint
was AF termination or 10% AF slowing (15 ms to 20
ms prolongation of AF cycle length), selected as a rigorous
marker of AF modulation (prior studies used AF slowing by
ablation of 6 ms3% to 4%) (28). The AF cycle length was
measured as the average in multiple samples over 5 min.
he pre-specified primary long-term efficacy endpoint
as defined as freedom from AF for up to 2 years after a
ingle procedure (median 273 days, interquartile range
IQR]: 132 to 681 days), defined as 1% burden using
ontinuous implanted ECG monitors, or AF 30 s on
ntermittent monitors (3). Secondary efficacy measures
ncluded freedom from AF in patients undergoing their
rst ablation, and freedom from all atrial arrhythmias.
he safety endpoint was a comparison of adverse events
etween groups.
tatistical analysis. Continuous data are represented as
ean  SD or median and IQR as appropriate. Normality
was evaluated using the Kolmogorov-Smirnov test. Com-
parisons between 2 groups were made with Student’s t tests
and summarized with means and standard deviations for
independent samples if normally distributed or, if not
normally distributed, evaluated with the Mann-Whitney U
test and summarized with medians and quartiles. Nominal
values are expressed as n (%) and compared with chi-square
tests or the Fisher exact test for comparisons when expected
cell frequency was 5. Associations between continuous
variables were evaluated with Spearman’s correlation. Raw
event rates were compared with chi-square tests, and event-
Figure 3 Acute Termination of AF, 2 Sources, to Sinus Rhythm
(A) Right atrial rotor (clockwise) and simultaneous left atrial focal impulse (arrowe
rotor modulation (FIRM) ablation at right atrial rotor terminated AF to sinus rhythm
left atrial focal impulse source was also treated by FIRM ablation. The patient is A
tions as in Figure 1. CS  coronary sinus electrogram.free survival plots were made by the Kaplan-Meier
method and compared with log-rank tests. A probability
of  0.05 was considered statistically significant through-
out. Analysis was by intention to treat, and crossovers
were not permitted.
Results
Table 1 summarizes the characteristics of our study popu-
lation. Persistent AF was present in 81% of the FIRM-
guided group, and in 66% of the FIRM-blinded group.
Prevalence and characteristics of localized sources for
human AF. Electrical rotors and focal impulses were pres-
ent in 98 of 101 cases with sustained AF (97%), each subject
demonstrating 2.1  1.0 sources (median 2, IQR: 1 to 3) of
hich 70% were rotors and 30% focal impulses. For the AF
otor in Figure 1C, Figure 1D shows the corresponding
lectrical circuit (arrows) in noise-reduced AF signals, that
recessed within an area of 1 to 2 cm2 in the low left atrium
Online Videos 1, 2, and 3).
The AF sources, conserved for at least tens of minutes
uring mapping (FIRM-guided cases), and lay in wide-
pread locations in the left atrium (76%) including sites
utside the pulmonary veins, posterior, inferior, roof and
nterior regions, and in the right atrium (24%) including the
nferolateral, posterior, and septal regions. When sources
ere present, their number was higher for persistent than
or paroxysmal AF (2.2  1.0 vs. 1.7  0.9; median 2.0 vs.
.0; p 0.03) and for spontaneous versus induced (typically
aroxysmal) AF (2.1 1.1 vs. 1.6 0.9; median 2.0 vs. 1.0;
 0.01), but was unrelated to age (r  0.13, p  0.20),
istorical duration of AF (r  0.14, p  0.17), or whether
ubjects were undergoing first ablation or had had prior
onventional ablation (2.1  1.1 vs. 2.0  0.8; median 2.0
s. 2.0; p  0.71).
IRM Ablation
ing persistent atrial fibrillation (AF) in a 47-year-old man. (B) Focal impulse and
min (Online Videos 4 and 5). Note the slowing of AF rate during ablation. The
on implanted cardiac monitor at 1 year. Scale bars 1 cm, 1 s. Atrial orienta-by F
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August 14, 2012:628–36 Ablation at AF SourcesAcute results of FIRM ablation. In Figures 2 and 3,
FIRM ablation alone before conventional ablation termi-
nated AF to sinus rhythm with 1 min FIRM ablation at
a left atrial rotor (Fig. 2), and with 5.5 min FIRM ablation
at a right atrial rotor (Fig. 3).
By intention-to-treat analysis, FIRM ablation alone
achieved the acute endpoint in 31 of 36 (86%) patients. The
AF terminated in 20 of 36 cases (56%) with 4.3  6.3 min
of FIRM ablation at the primary source (median 2.5 min,
IQR: 1.0 to 3.1 min) (Table 2). In the 11 of 36 cases in
whom AF did not terminate, AF slowed by 33  12 ms
(19  8%). Cases in whom FIRM ablation slowed rather
than terminated AF had larger LA diameters (53  8 mm
vs. 46  6 mm; p  0.01) and more patients with LA
diameter 55 mm (poor coverage because the LA was too
large for the largest basket; 8 of 11 vs. 1 of 20; p  0.001,
Fisher exact test). FIRM ablation could not be completed in
4 of 36 cases in whom sources lay near the phrenic nerve, an
atrial pacing lead, the compact AV node, and esophagus;
and FIRM ablation was not performed in 1 case without
identified sources. Total FIRM ablation time (at all targeted
sources) was 16.1 9.8 min (median 18.5 min, IQR: 7.9 to
24.5 min) (Table 2).
By comparison, in the FIRM-blinded group, the acute
endpoint was achieved in 13 of 65 cases with sustained AF
(20%) after 43.4  28.0 min (median 31.8 min, IQR: 22.1
to 71.5 min) ablation (p  0.001 for both comparisons
against FIRM-guided limb).
Long-term efficacy. Two subjects in each group were
lost to follow-up. By intention-to-treat analysis, single-
procedure freedom from AF was higher for FIRM-guided
than for FIRM-blinded cases (82.4% [28 of 34] vs. 44.9%
Acute Results in All Cases or Those With SustaTable 2 Acute Results in All Cases or Those
Characteristic Conven
Cases with intraprocedural sustained AF 65
Subjects with AF sources 63
Acute endpoint achieved 13
AF termination endpoint 6
Ablation time, min, at primary source
To sinus rhythm/atrial tachycardia
AF slowing (CL prolongation) endpoint 7/
Extent of AF CL prolongation, ms 28
Ablation time for acute endpoint, min 31.8
Total procedural ablation (all cases), min 52
Complications, all cases
Cardiac tamponade
Groin bleed requiring transfusion
Vascular injury requiring surgical repair
Permanent diaphragmatic paralysis
Symptomatic pulmonary vein stenosis
Stroke/TIA
Atrioesophageal fistula
DeathValues are n/N (%), mean  SD, median (interquartile range), n (%), or n. *R
CL  cycle length; other abbreviations as in Table 1.[31 of 69]; p  0.001) after median 273 days (IQR: 132 to
681 days). FIRM-guided therapy maintained its treatment
benefit over FIRM-blinded therapy for first-time ablation
cases (p  0.001). No FIRM-guided case recurred after 7
onths as determined using mostly implanted ECG mon-
toring. Results were similar excluding subjects without AF
ho remained on antiarrhythmic medications because of
eferring physician preference (79.3% [23 of 29] FIRM-
uided vs. 35.6% [21 of 59] FIRM-blinded; p  0.001).
reedom from any atrial tachyarrhythmia after a single
rocedure was also higher in FIRM-guided than in FIRM-
linded cases (70.6% [24 of 34] vs. 39.1% [27 of 69]; p 
.003).
Kaplan-Meier survival plots are illustrated in Figure 4.
ollow-up was more rigorous in the FIRM-guided group
han in the FIRM-blinded group (implantable ECG mon-
tors in 30 of 34 [88.2%] vs. 18 of 69 [26.1%]; p  0.001).
Online Figures 1 and 2 present examples of continuous and
intermittent ECG monitoring for recurrent AF. Patients
defined as ‘without AF’ (1% burden) actually had 0.1 
0.2% burden. Neither the total duration of ablation, the
aggregate number, nor the type of adverse events differed
between groups (Table 2).
Discussion
The CONFIRM trial demonstrates for the first time that
human AF may be sustained by localized sources in the
form of electrical rotors and focal impulses. Brief ablation
(FIRM) at patient-specific AF-sustaining sources was able
to terminate or consistently slow persistent or paroxysmal
AF before any conventional ablation in 86% of patients, and
AF During Their Procedureh Sustained AF During Their Procedure
Ablation FIRM-Guided Ablation p Value
2%) 36/36 (100%) 0.10
7%) 35/36 (97%) 1.00
0%) 31/36 (86%) 0.001
%) 20/36 (56%) 0.001
2.5 (1.0–3.1)
16/4 0.29
%) 11/36 (31%) 0.01
 6%) 33 12 (19 8%) 0.38
71.5) 18.5 (7.9–24.5) 0.001
7.8 57.8 22.8 0.16
2 (6%) 0.72
1
1
0
0
0
0
0
0inedWit
tional
/71 (9
/65 (9
/65 (2
/65 (9
—
3/3
65 (11
8 (18
(22.1–
.1 1
6 (8%)
2
3
0
0
1*
0
0
0equired stent.
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Ablation at AF Sources August 14, 2012:628–36substantially increase long-term AF elimination using very
rigorous monitoring compared to conventional AF ablation
alone.
Localized sources for human AF. Electrical rotors in
human AF were revealed using a novel computational
mapping approach that analyzes electrograms in a wide
atrial field of view in the context of physiologically plausible
activation rates and conduction dynamics (23–26). No prior
trial has identified or successfully targeted localized human
AF sources for acute AF termination and elimination on
follow-up. However, a number of elegant reports have
characterized organized reentry before AF (29), transient
rotors in AF (21,22), and sites of rapid (17,18,30,31) or
disorganized (32) AF.
The mechanistic role of rotors and focal sources in
perpetuating AF is demonstrated by acute AF termination
by brief FIRM ablation alone, as we recently illustrated in a
video case report (33). Patients in whom FIRM ablation
slowed rather than terminated AF had sources that could
not be eliminated, for safety considerations or protocol-
imposed time limits, or had atria larger than current baskets
(illustrated in Narayan [23]) and may have had residual
Figure 4 Cumulative Freedom From Primary Endpoint
Cumulative freedom from atrial fibrillation, in all cases and in those at first
ablation for (A) the entire population and (B) the population off anti-arrhythmic
medications. Intention-to-treat analysis and p values reflect the complete
follow-up period. Solid red lines indicate focal impulse and rotor modulation
(FIRM)-blinded; solid blue lines indicate FIRM-guided; dashed red lines  FIRM-
blinded first ablation; dashed blue lines indicate FIRM-guided first ablation.sources in unmapped regions. In fact, intracardiac atrialdimensions were substantially larger than reported prepro-
cedural estimates. Rotors and focal sources were clinically
relevant long-term AF perpetuators based on improved AF
elimination using FIRM-guided versus conventional abla-
tion.
Human AF rotors and focal impulses were fewer in
number, longer lived, and more conserved in this study than
suggested (20,21). That alters our conceptual framework for
human AF, and enabled FIRM ablation to be practical and
effective. Future work should study whether structural (34)
or electrical (14) remodeling, altered innervation (35), or
other processes explain these differences in AF. The similar
number of sources for patients with and without prior
ablation suggests, on the one hand, that prior ablation did
not create sources and, on the other hand, that prior
ablation may have been unsuccessful because it did not
eliminate these AF sources. Both hypotheses require further
testing.
Efficacy of FIRM-guided ablation. The FIRM-guided
ablation was more effective than conventional ablation for
patients undergoing their first procedure (Fig. 4) as well as
for patients with prior conventional ablation, who were
included to compare the mechanisms of AF across a wide
range of presentations. Moreover, FIRM-guided ablation
showed substantial efficacy benefit despite the use of highly
sensitive implanted ECG monitors in 88% of cases. This is
the highest usage of implanted ECG monitors in any AF
treatment trial. The use of symptoms or intermittent ECG
monitoring in prior AF therapy trials (7,27) likely underes-
timated the full burden of AF recurrence. Because only 26%
of FIRM-blinded cases received implanted monitors, stud-
ies on the comparative efficacy of AF monitoring strategies
(7,27) suggest that the CONFIRM study may actually
underestimate the relative benefit of FIRM-guided over
conventional ablation by 10%.
FIRM-guided and conventional ablation. The AF
sources in this study are consistent with, and may explain,
the results of conventional AF ablation. First, most sources
lay in the left atrium, supporting current guidelines that
primarily advocate left atrial ablation (3). Interestingly, the
presence of right atrial sources in one-quarter of patients
may explain the 70% to 80% success ceiling of conventional
predominantly left atrial ablation for paroxysmal (6) and
persistent (9) AF. Notably, prior studies that included right
atrial ablation (36) achieved higher success rates. Second,
diverse source locations are consistent with reports that
widespread ablation may be required in both atria (10).
Third, the higher number of sources in persistent than
paroxysmal AF is consistent with lower success and more
difficult procedures in the former group.
In the CONFIRM study, FIRM-guided ablation was
followed by pulmonary vein isolation, yet total ablation time
did not differ between groups (Table 2) because the brief
duration of FIRM ablation fell within case-to-case varia-
tions of conventional ablation time. Accordingly, FIRM-
guided therapy presents an opportunity to improve ablation
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result in serious sequelae (3).
Study limitations. This study has the limitations of a
nonrandomized design. However, subjects were enrolled
consecutively and treated prospectively for pre-specified
endpoints. First, the FIRM-guided group had more subjects
with persistent AF, higher comorbidity, and more intense
monitoring than FIRM-blinded subjects, thus potentially
underestimating the benefit of FIRM-guided ablation. Sec-
ond, although the basket may have suboptimal resolution
for a small focal origin or rotor core (16), an AF source will
“control” a larger ‘organized domain’ of the atrium for which
the basket field of view is well suited to map in clinical
practice. The size of a single ablation lesion (5 to 7 mm
diameter) also places a practical limit on the necessary
resolution. conversely, the largest available diameter (55 to
60 mm when fully deployed) limits the largest atrial size that
can be mapped. Third, more extensive FIRM ablation at
sources beyond the 3 protocol limit may have yielded
higher rates of AF termination and long-term success, but
was not performed because of the study design. Future
studies will target all detected sources for FIRM ablation.
Finally, this first trial of FIRM-guided ablation needs
validation in larger populations, with balanced representa-
tion of the sexes, by many more investigators, and in
randomized fashion. Such validation is already under way.
Conclusions
Human AF is typically caused by very few localized sources
that cause disorganization in the remaining atria. Focal
impulse and rotor modulation (FIRM) ablation to eliminate
these sources was able to abruptly terminate or consistently
slow persistent and paroxysmal AF in the vast majority of
cases, and substantially improve long-term AF elimination
over conventional ablation alone in this prospective case-
cohort study. FIRM mapping may open the possibility for
several patient-tailored therapies for AF in addition to
ablation for this highly prevalent disease with major public
health and societal impact.
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APPENDIX
For a supplemental Methods section and supplemental figures,
videos, and references, please see the online version of this article.
